Logo image of GRPH

GRAPHITE BIO INC (GRPH) Stock Fundamental Analysis

NASDAQ:GRPH - Nasdaq - US38870X1046 - Common Stock - Currency: USD

3.18  -0.09 (-2.75%)

After market: 3.22 +0.04 (+1.26%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to GRPH. GRPH was compared to 558 industry peers in the Biotechnology industry. While GRPH has a great health rating, there are worries on its profitability. GRPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GRPH had negative earnings in the past year.
In the past year GRPH has reported a negative cash flow from operations.
In the past 5 years GRPH always reported negative net income.
In the past 5 years GRPH always reported negative operating cash flow.
GRPH Yearly Net Income VS EBIT VS OCF VS FCFGRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of GRPH (-66.14%) is worse than 63.44% of its industry peers.
GRPH has a Return On Equity (-67.90%) which is in line with its industry peers.
Industry RankSector Rank
ROA -66.14%
ROE -67.9%
ROIC N/A
ROA(3y)-38.38%
ROA(5y)N/A
ROE(3y)-40.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRPH Yearly ROA, ROE, ROICGRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRPH Yearly Profit, Operating, Gross MarginsGRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

GRPH has less shares outstanding than it did 1 year ago.
There is no outstanding debt for GRPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRPH Yearly Shares OutstandingGRPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
GRPH Yearly Total Debt VS Total AssetsGRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

GRPH has an Altman-Z score of 19.96. This indicates that GRPH is financially healthy and has little risk of bankruptcy at the moment.
GRPH has a Altman-Z score of 19.96. This is amongst the best in the industry. GRPH outperforms 91.84% of its industry peers.
There is no outstanding debt for GRPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.96
ROIC/WACCN/A
WACCN/A
GRPH Yearly LT Debt VS Equity VS FCFGRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

GRPH has a Current Ratio of 39.20. This indicates that GRPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 39.20, GRPH belongs to the top of the industry, outperforming 98.98% of the companies in the same industry.
A Quick Ratio of 39.20 indicates that GRPH has no problem at all paying its short term obligations.
GRPH has a Quick ratio of 39.20. This is amongst the best in the industry. GRPH outperforms 98.98% of its industry peers.
Industry RankSector Rank
Current Ratio 39.2
Quick Ratio 39.2
GRPH Yearly Current Assets VS Current LiabilitesGRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GRPH have decreased strongly by -18.38% in the last year.
EPS 1Y (TTM)-18.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GRPH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.20% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y81.37%
EPS Next 2Y34.67%
EPS Next 3Y21.95%
EPS Next 5Y9.2%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

GRPH Yearly Revenue VS EstimatesGRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2029 2030 20M 40M 60M 80M 100M
GRPH Yearly EPS VS EstimatesGRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRPH Price Earnings VS Forward Price EarningsGRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRPH Per share dataGRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as GRPH's earnings are expected to grow with 21.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.67%
EPS Next 3Y21.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GRPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAPHITE BIO INC

NASDAQ:GRPH (3/21/2024, 8:00:01 PM)

After market: 3.22 +0.04 (+1.26%)

3.18

-0.09 (-2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2024-02-27/amc
Earnings (Next)N/A N/A
Inst Owners1.1%
Inst Owner Change0%
Ins Owners61.25%
Ins Owner Change0%
Market Cap184.47M
Analysts43.33
Price Target7.14 (124.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-128.01%
Min EPS beat(2)-204%
Max EPS beat(2)-52.03%
EPS beat(4)0
Avg EPS beat(4)-123.22%
Min EPS beat(4)-209.77%
Max EPS beat(4)-27.1%
EPS beat(8)3
Avg EPS beat(8)-61.61%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.14%
ROE -67.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.38%
ROA(5y)N/A
ROE(3y)-40.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 451.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 39.2
Quick Ratio 39.2
Altman-Z 19.96
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)505.92%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.09%
EPS Next Y81.37%
EPS Next 2Y34.67%
EPS Next 3Y21.95%
EPS Next 5Y9.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y30.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.3%
OCF growth 3YN/A
OCF growth 5YN/A